Transoral Gastroplasty for the Treatment of Morbid Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

275 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The TOGA® trial is a prospective, multi-center, randomized sham-controlled trial designed to determine the safety and effectiveness of the TOGA System for the treatment of morbid obesity. The study will also determine the effect of the treatment on co-morbidities and quality of life.

Subjects will be blinded to treatment or sham. Sham arm may crossover to TOGA treatment at 12 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endoscopic Bariatric Stapling Pilot Study

NCT01067625

Obesity

UNKNOWN PHASE1

Comparing Reduction With ESD- Versus APC-TORe

NCT06131281

Obesity Roux-en-y Anastomosis Site Weight Gain

RECRUITING NA

Gastric Plication and Banding

NCT02072395

Morbid Obesity

COMPLETED PHASE2

Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates

NCT00721227

Obesity

COMPLETED NA

Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication

NCT01077193

Morbid Obesity

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TOGA

The TOGA procedure is an incision-free treatment using a set of flexible staplers introduced into the mouth and esophagus to create a sleeve in the stomach (transoral formation of a gastric sleeve). The TOGA sleeve limits the amount of food that can be eaten and gives the patient a feeling of fullness after a small meal.

Group Type EXPERIMENTAL

TOGA

Intervention Type DEVICE

Transoral Gastroplasty (TOGA®) System for gastric stapling.

Control

A gastric sleeve is not formed.

Group Type SHAM_COMPARATOR

Control

Intervention Type DEVICE

The control device (bougie dilator) is a FDA-cleared (Class II) device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TOGA

Transoral Gastroplasty (TOGA®) System for gastric stapling.

Intervention Type DEVICE

Control

The control device (bougie dilator) is a FDA-cleared (Class II) device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-60
2. BMI ≥ 40 kg/m2 and \< 55 kg/m2, or BMI ≥ 35 kg/m2 with one or more significant co morbidities
3. History of obesity for at least 2.5 years.
4. History of stable weight (defined as a \< 10% change in excess weight) for one year prior to the screening visit.
5. History of failure with non-surgical weight loss methods.
6. Suitable candidate for bariatric surgery based on the results of their psychological and physical evaluations.
7. Understands risks of procedure, agrees to follow protocol requirements, including signing informed consent, returning for follow-up visits, completing all required testing, completing diet and behavior modification counseling, committing to prolonged lifestyle changes, and agrees to comply with the substantial dietary restrictions required by the procedure.
8. Subject lives, and intends to remain, within a 100 mile radius of the study center for 5 years.

Exclusion Criteria

1. Hormonal or genetic cause for the obese state.
2. History of cancer other than localized basal cell carcinoma.
3. History of inflammatory disease of the gastrointestinal tract including Crohn's disease, ulcerative colitis, severe intractable esophagitis, gastric ulceration, or esophageal or duodenal ulceration.
4. Active peptic ulcer disease.
5. Significant known esophageal disease, including Zenker's diverticulum, grade 3-4 reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal diverticulum, dysphagia, achalasia, diffuse esophageal spasm, and symptoms of dysmotility.
6. Myocardial infarction or cerebrovascular accident within past year.
7. Angina pectoris.
8. Inability to extend neck or fully open mouth.
9. Clinically severe cervical spinal disease, including cervical disc disease, vertebral osteophytes.
10. Critically loose teeth.
11. Temporomandibular joint syndrome (TMJ) or patients at risk for developing TMJ.
12. Severe coagulopathy (prothrombin time \> 3 seconds over control or platelet count \< 100,000)
13. Gastroparesis
14. Upper GI bleeding conditions such as esophageal or gastric varices, portal hypertensive gastropathy, congenital or acquired intestinal telangiectasis.
15. Congenital or acquired anomalies of the GI tract such as atresias or stenoses.
16. Structural abnormalities of the GI tract such as diverticulum.
17. Lesions with increased risk of bleeding.
18. Hiatal hernia ≥ 2cm.
19. Severe cardiopulmonary disease or other serious organic disease, including HIV or cancer.
20. Congestive heart failure.
21. Uncontrolled hypertension (systolic \>150 or diastolic \> 100).
22. Advanced rheumatoid arthritis.
23. Severe or advanced liver disease (such as cirrhosis, chronic hepatitis, portal hypertension, etc.).
24. Chronic pancreatitis.
25. Any contraindication to endoscopy.
26. Severe reflux disease.
27. Currently pregnant or nursing.
28. Potentially childbearing (i.e. not post-menopausal or surgically sterilized) and not willing to use an effective method of contraception for the next 24 months.
29. Alcohol (\> 80 gm/day of ethanol) or illicit drug use within the last 3 years.
30. Prior gastric, esophageal, pancreatic or bariatric surgery.
31. Currently on prescription or over the counter diet drugs.
32. Chronic therapy with aspirin, NSAID or anticoagulants.
33. Systemic infection at the time of the procedure.
34. Patient with a known diagnosis or pre-existing symptoms of autoimmune connective tissue disease (i.e., systemic lupus erythematosus or scleroderma).
35. Thyroid disease which is not controlled with medication
36. Unacceptable medical risk (general health status would preclude surgery should a complication occur).
37. Not ambulatory.
38. Participating in another ongoing clinical trial in which concomitant diagnosis or therapeutic intervention would adversely affect the integrity of the clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No